Structural Genomics Consortium: Innovation in Big Pharma

In 2005, Henry Goodman was head of the Protein Structure Group at Novartis. He had just finished reading an email from Brian Johnson who had a similar position at GlaxoSmithKline, one of Novartis’ main competitors. Brian had approached Henry with an invitation to join the ‘Structural Genomics Consortium’ (SGC), an academic-industrial collaboration in the areas of structural genomics. GlaxoSmithKline was one of the founders of the Consortium and at this time its only corporate member, but the organization was now looking to sign up further pharma companies to take part in this joint venture.


Topics/Industry: big pharmainnovation strategypharmaceuticals

Publication date: 01/03/2017

Published by: Imperial College Business School

Authors: Markus Perkmann

Length: 7 pages

Geography: UK

Internal users

External users

This case is not available to external audiences at this time.